Open AccessMYD88 L265P mutation in intraocular lymphoma: A potential diagnostic marker
Author(s) -
Sandhya Narasimhan,
Mayur Joshi,
Sowmya Parameswaran,
Pukhraj Rishi,
Vikas Khetan,
Suganeswari Ganesan,
Jyotirmay Biswas,
Sundaram Natarajan,
Janani Sreenivasan,
Sonali Verma,
Vanitha Krishnamurthy,
Subramanian Krishnakumar
Publication year - 2020
Publication title -
indian journal of ophthalmology/indian journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 51
eISSN - 1998-3689
pISSN - 0301-4738
DOI - 10.4103/ijo.ijo_1712_19
Subject(s) - medicine , intraocular lymphoma , lymphoma , mutation testing , mutation , pathology , biopsy , genetics , biology , gene
Vitreoretinal lymphoma (VRL) is the most common intraocular lymphoma (IOL). This can be either primary or secondary to the central nervous system lymphoma. The diagnosis of primary intraocular lymphoma (PIOL) currently relies on clinical diagnosis and cytological analysis of the vitreous or subretinal biopsy. Although most cases are diagnosed without much issue, the limited amount of vitreous fluid, subjectivity in cytological reporting, and special expertise in ocular pathology make the diagnosis challenging. MYD88 L265P mutation has been implicated to have diagnostic utility in PIOL. In this study, we screened consecutive vitreous biopsies for the presence of MYD88 L265P mutation to understand its diagnostic utility compared to conventional cytological analysis.